Phio Pharmaceuticals Corp. — Form 8-K
Filed September 28, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 72/100
What the filing says
Phio Pharmaceuticals' Board and Compensation Committee approved an amendment to increase the 2020 Long-Term Incentive Plan share reserve by 1,500,000 shares, raising the total available from 952,017 to 2,452,017 shares, pending shareholder approval. This allows for up to $500,000 annual equity grants to non-employee directors and increases equity pool available for employee and director compensation. The amendment is effective only upon stockholder approval.
Why this rating
1.5M share increase is ~13% of current market value ($11.2M); material for compensation but routine governance. Neutral because outcome depends on shareholder vote; no imminent business impact.
Price action (we called it neutral)
before filing · preread $1.01 ▲ 0.00% | at our read · unknown $1.01 | +10 min · unknown $1.04 ▲ 2.97% | +30 min · unknown $1.03 ▲ 2.48% | +1 hr · unknown $1.04 ▲ 2.97% | +4 hrs · unknown $1.02 ▲ 0.99% |
The stock had already moved +0.00% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.